| TAH Drug Code | INIM |
|---|---|
| Indications | Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage. |
| Dosing | Subarachnoid hemorrhage, From ruptured intracranial berry aneurysms prophylaxis: initial, 0.5 mg/hr (hemadynamics unstable patient) to 1mg/hr (15mcg/kg/hr) for 2hr, then slowly titrate to 2mg/hr. (usually start drug within 4 days, then keep therapy for10-14days. if Craniotomy: continue IVD for at least 5 days after craniotomy. Then switch to orally 60mg Q4H for 7 days. treatment: initial, 1mg/hr (15mcg/kg/hr) for 2hr, then slowly titrate to 2mg/hr for 5-14days. after that, switch to orally 60mg Q4H for 7 days. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Must not be administered to patients with severely impaired liver function |
| Adverse Effects | Hypotension, GI disturbances. |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Risk |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |
| TAH Drug Code | ONIM |
|---|---|
| Indications | Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage. |
| Dosing | Subarachnoid hemorrhage, From ruptured intracranial berry aneurysms: treatment or prophylaxis: 60mg Q4H for 7 days (1 hour before or 2 hours after meals), after IV infusion Nimotop for 5-14 days. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Patients with severely impaired liver function (eg, cirrhosis of the liver). In view of its indication area, Nimotop tablet is not used during pregnancy or lactation. |
| Adverse Effects | Hypotension, GI disturbances. |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Risk |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |